

Gabriella Gobbi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9156266/publications.pdf>

Version: 2024-02-01

115
papers

7,455
citations

46918

47
h-index

56606

83
g-index

124
all docs

124
docs citations

124
times ranked

7799
citing authors

#	ARTICLE	IF	CITATIONS
1	Parental Death During Adolescence: A Review of the Literature. <i>Omega: Journal of Death and Dying</i> , 2023, 87, 1207-1237.	0.7	9
2	Investigation of the Relationship among Cortisol, Pro-inflammatory Cytokines, and the Degradation of Tryptophan into Kynurenine in Patients with Major Depression and Suicidal Behavior. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 2119-2125.	1.0	18
3	Distinct Effects of Antidepressants in Association With Mood Stabilizers and/or Antipsychotics in Unipolar and Bipolar Depression. <i>Journal of Clinical Psychopharmacology</i> , 2022, Publish Ahead of Print, .	0.7	2
4	Examining the association between duration of untreated illness and clinical outcomes in patients with major depressive and bipolar disorders. <i>Journal of Affective Disorders Reports</i> , 2022, 8, 100324.	0.9	0
5	Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 479-488.	1.0	14
6	Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. <i>Neuropsychopharmacology</i> , 2022, 47, 1188-1198.	2.8	36
7	Radiosynthesis and <i>In Vivo</i> Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1382-1394.	1.7	4
8	Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 119, 110594.	2.5	14
9	Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. <i>Journal of Neuroscience</i> , 2021, 41, 891-900.	1.7	99
10	Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. <i>Pharmacological Reviews</i> , 2021, 73, 202-277.	7.1	110
11	Antidepressant actions of ketamine engage cell-specific translation via eIF4E. <i>Nature</i> , 2021, 590, 315-319.	13.7	68
12	Franco Fraschini, MD, PhD (1932-2020). <i>Journal of Pineal Research</i> , 2021, 70, .	3.4	0
13	Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	55
14	Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice. <i>Journal of Psychopharmacology</i> , 2021, 35, 469-482.	2.0	24
15	<i>N</i> -(Anilinoethyl)amide Melatonergic Ligands with Improved Water Solubility and Metabolic Stability. <i>ChemMedChem</i> , 2021, 16, 3071-3082.	1.6	6
16	Lifetime Cannabis Use Disorder Is Not Associated With Lifetime Impulsive Behavior and Severe Violence in Patients With Schizophrenia Spectrum Disorders From a High-Security Hospital. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 623-628.	0.7	2
17	Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder. <i>Frontiers in Pharmacology</i> , 2021, 12, 749068.	1.6	16
18	A Key Role for Prefrontocortical Small Conductance Calcium-Activated Potassium Channels in Stress Adaptation and Rapid Antidepressant Response. <i>Cerebral Cortex</i> , 2020, 30, 1559-1572.	1.6	7

#	ARTICLE	IF	CITATIONS
19	Effects of Chronic Exposure to Low-Dose delta-9-Tetrahydrocannabinol in Adolescence and Adulthood on Serotonin/Norepinephrine Neurotransmission and Emotional Behavior. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 751-761.	1.0	22
20	Nociceptive responses in melatonin MT ₂ receptor knockout mice compared to MT ₁ and double MT ₁ /MT ₂ receptor knockout mice. <i>Journal of Pineal Research</i> , 2020, 69, e12671.	3.4	16
21	Dysfunction of serotonergic activity and emotional responses across the light/dark cycle in mice lacking melatonin MT ₂ receptors. <i>Journal of Pineal Research</i> , 2020, 69, e12653.	3.4	17
22	Melatonin MT1 and MT2 Receptors Exhibit Distinct Effects in the Modulation of Body Temperature across the Light/Dark Cycle. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2452.	1.8	20
23	Melatonin MT1 receptor as a novel target in neuropsychopharmacology: MT1 ligands, pathophysiological and therapeutic implications, and perspectives. <i>Pharmacological Research</i> , 2019, 144, 343-356.	3.1	38
24	Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep. <i>Frontiers in Endocrinology</i> , 2019, 10, 87.	1.5	93
25	A role for cannabidiol in psychiatry? Keep calm and follow the drug development rules. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 98-100.	1.3	2
26	Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood. <i>JAMA Psychiatry</i> , 2019, 76, 426.	6.0	519
27	Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. <i>Pain</i> , 2019, 160, 136-150.	2.0	239
28	Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep. <i>Journal of Pineal Research</i> , 2019, 66, e12544.	3.4	40
29	Role of palmitoylethanolamide (PEA) in depression: Translational evidence. <i>Journal of Affective Disorders</i> , 2019, 255, 195-200.	2.0	22
30	Trace elements among a sample of prisoners with mental and personality disorders and aggression: correlation with impulsivity and ADHD indices. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019, 51, 123-129.	1.5	10
31	Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 703-711.	1.3	61
32	Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. <i>Pharmacological Reviews</i> , 2018, 70, 197-245.	7.1	231
33	Psychopathological and sociodemographic features in treatment-resistant unipolar depression versus bipolar depression: a comparative study. <i>BMC Psychiatry</i> , 2018, 18, 68.	1.1	17
34	High frequency stimulation of the anterior vermis modulates behavioural response to chronic stress: involvement of the prefrontal cortex and dorsal raphe?. <i>Neurobiology of Disease</i> , 2018, 116, 166-178.	2.1	16
35	Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression. <i>International Clinical Psychopharmacology</i> , 2018, 33, 34-43.	0.9	22
36	Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain. <i>Current Medicinal Chemistry</i> , 2018, 25, 3866-3882.	1.2	44

#	ARTICLE	IF	CITATIONS
37	d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. <i>Progress in Brain Research</i> , 2018, 242, 69-96.	0.9	61
38	Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E. <i>Nature Communications</i> , 2018, 9, 2459.	5.8	65
39	Practitioner Review: The effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2017, 58, 865-879.	3.1	9
40	Lurasidone and Mood Stabilizers in Treatment-Resistant Unipolar Depression. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 263-264.	0.7	0
41	D-lysergic diethylamide modulates dopaminergic neurons of ventral tegmental area via 5-HT _{1A} , D ₂ and TAAR1 receptors. <i>European Neuropsychopharmacology</i> , 2017, 27, S53-S54.	0.3	0
42	Serotonin transporter gene promoter methylation in peripheral cells in healthy adults: Neural correlates and tissue specificity. <i>European Neuropsychopharmacology</i> , 2017, 27, 1032-1041.	0.3	16
43	Effects of δ^9 -Tetrahydrocannabinol, Synthetic Cannabinoids, and Fatty Acid Amide Hydrolase Inhibitors on Mood and Serotonin Neurotransmission. , 2016, , 815-826.		0
44	d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1953.	1.8	76
45	Tryptophan via serotonin/kynurenine pathways abnormalities in a large cohort of aggressive inmates: markers for aggression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 70, 8-16.	2.5	48
46	Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review. <i>Pharmacological Reviews</i> , 2016, 68, 563-602.	7.1	186
47	The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT _{1A} , D ₂ and TAAR 1 receptors. <i>Pharmacological Research</i> , 2016, 113, 81-91.	3.1	76
48	The fatty acid amide hydrolase inhibitor URB597 modulates serotonin-dependent emotional behaviour, and serotonin _{1A} and serotonin _{2A/C} activity in the hippocampus. <i>European Neuropsychopharmacology</i> , 2016, 26, 578-590.	0.3	31
49	Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 165-170.	1.3	21
50	Translational Research in Suicide: Is It Possible to Study Suicide in Animal Models?. , 2016, , 177-188.		5
51	Short-Term Natural Course of Depressive Symptoms and Family-Related Stress in Adolescents after Separation from Father. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 417-426.	0.9	4
52	Melancholic-Like Behaviors and Circadian Neurobiological Abnormalities in Melatonin MT ₁ Receptor Knockout Mice. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu075-pyu075.	1.0	56
53	Antinociceptive properties of selective MT ₂ melatonin receptor partial agonists. <i>European Journal of Pharmacology</i> , 2015, 764, 424-432.	1.7	32
54	Selective melatonin MT ₂ receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways. <i>Pain</i> , 2015, 156, 305-317.	2.0	68

#	ARTICLE	IF	CITATIONS
55	Anatomical and cellular localization of melatonin MT_1 and MT_2 receptors in the adult rat brain. <i>Journal of Pineal Research</i> , 2015, 58, 397-417.	3.4	142
56	Monoamine oxidase a gene promoter methylation and transcriptional downregulation in an offender population with antisocial personality disorder. <i>British Journal of Psychiatry</i> , 2015, 206, 216-222.	1.7	91
57	Father Absence in the Monogamous California Mouse Impairs Social Behavior and Modifies Dopamine and Glutamate Synapses in the Medial Prefrontal Cortex. <i>Cerebral Cortex</i> , 2015, 25, 1163-1175.	1.6	30
58	Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: a pilot randomized, open-label, comparative study. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 757.	1.0	9
59	Unveiling the role of melatonin MT_2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, 6-21.	1.4	142
60	Quetiapine in Postpartum Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 744-745.	0.7	5
61	Chronic nandrolone decanoate exposure during adolescence affects emotional behavior and monoaminergic neurotransmission in adulthood. <i>Neuropharmacology</i> , 2014, 83, 79-88.	2.0	33
62	S.27.01 Novel selective melatonin MT_2 receptor agonist in the treatment of insomnia. <i>European Neuropsychopharmacology</i> , 2014, 24, S144.	0.3	0
63	Electrophysiological characterization of dopamine neuronal activity in the ventral tegmental area across the light-dark cycle. <i>Synapse</i> , 2014, 68, 454-467.	0.6	39
64	Melatonin, selective and non-selective MT_1/MT_2 receptors agonists: Differential effects on the 24-h vigilance states. <i>Neuroscience Letters</i> , 2014, 561, 156-161.	1.0	27
65	Male Inmate Profiles and Their Biological Correlates. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 441-449.	0.9	19
66	Sleep-wake characterization of double MT_1/MT_2 receptor knockout mice and comparison with MT_1 and MT_2 receptor knockout mice. <i>Behavioural Brain Research</i> , 2013, 243, 231-238.	1.2	95
67	Modulation of Serotonin Firing Activity Through CB_1 Agonists and FAAH Inhibitors. , 2013, , 255-275.		0
68	The Psychopharmacology of Aggressive Behavior. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 237-260.	0.7	103
69	The Psychopharmacology of Aggressive Behavior. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 83-94.	0.7	106
70	Short-term effects of melatonin and pinealectomy on serotonergic neuronal activity across the light-dark cycle. <i>Journal of Psychopharmacology</i> , 2012, 26, 830-844.	2.0	30
71	Adolescent amphetamine exposure elicits dose-specific effects on monoaminergic neurotransmission and behaviour in adulthood. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1319-1330.	1.0	29
72	Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. <i>European Neuropsychopharmacology</i> , 2012, 22, 664-671.	0.3	91

#	ARTICLE	IF	CITATIONS
73	Cannabinoids and emotionality: a neuroanatomical perspective. <i>Neuroscience</i> , 2012, 204, 134-144.	1.1	71
74	Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 38, 88-96.	2.5	53
75	The selective neuropeptide Y Y5 agonist [cPP1 ⁷ ,NPY19 ²³ ,Ala31,Aib32,Gln34]hPP differently modulates emotional processes and body weight in the rat. <i>Behavioural Brain Research</i> , 2012, 233, 298-304.	1.2	16
76	Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 39, 318-325.	2.5	60
77	Characterization of serotonin neurotransmission in knockout mice: implications for major depression. <i>Reviews in the Neurosciences</i> , 2012, 23, 429-43.	1.4	38
78	Promotion of Non-Rapid Eye Movement Sleep and Activation of Reticular Thalamic Neurons by a Novel MT ₂ Melatonin Receptor Ligand. <i>Journal of Neuroscience</i> , 2011, 31, 18439-18452.	1.7	113
79	Schizophrenia and serious violence: A clinical-profile analysis incorporating impulsivity and substance-use disorders. <i>Schizophrenia Research</i> , 2011, 130, 234-237.	1.1	44
80	M-B-035 SLEEP IN MT2 MELATONIN RECEPTOR KNOCKOUT MICE. <i>Sleep Medicine</i> , 2011, 12, S32.	0.8	0
81	Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice. <i>Psychopharmacology</i> , 2011, 214, 465-476.	1.5	61
82	Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission. <i>Neurobiology of Disease</i> , 2010, 37, 641-655.	2.1	136
83	Evaluation of the Electromagnetic Hazard of intense THz pulses on neural cells. , 2010, , .		0
84	Genetic Deletion of Fatty Acid Amide Hydrolase Alters Emotional Behavior and Serotonergic Transmission in the Dorsal Raphe, Prefrontal Cortex, and Hippocampus. <i>Neuropsychopharmacology</i> , 2010, 35, 2083-2100.	2.8	113
85	Spadin, a Sortilin-Derived Peptide, Targeting Rodent TREK-1 Channels: A New Concept in the Antidepressant Drug Design. <i>PLoS Biology</i> , 2010, 8, e1000355.	2.6	151
86	Endocannabinoids in the Treatment of Mood Disorders: Evidence from Animal Models. <i>Current Pharmaceutical Design</i> , 2009, 15, 1623-1646.	0.9	85
87	<i>N</i>-((Anilinoethyl)amides: Design and Synthesis of Metabolically Stable, Selective Melatonin Receptor Ligands. <i>ChemMedChem</i> , 2009, 4, 1746-1755.	1.6	30
88	Monoaminergic Changes in Locus Coeruleus and Dorsal Raphe Nucleus Following Noradrenaline Depletion. <i>Neurochemical Research</i> , 2009, 34, 1417-1426.	1.6	41
89	Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009, 380, 383-397.	1.4	15
90	The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 484-493.	4.0	147

#	ARTICLE	IF	CITATIONS
91	Decline in serotonergic firing activity and desensitization of 5-HT _{1A} autoreceptors after chronic unpredictable stress. <i>European Neuropsychopharmacology</i> , 2009, 19, 215-228.	0.3	104
92	Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. <i>European Neuropsychopharmacology</i> , 2009, 19, 457-465.	0.3	122
93	An index of 5-HT synthesis changes during early antidepressant treatment: \pm -[11C]methyl-l-tryptophan PET study. <i>Neurochemistry International</i> , 2008, 52, 701-708.	1.9	62
94	Brain TRPV1: a depressing TR(i)P down memory lane?. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 594-600.	4.0	32
95	The cannabinoid CB ₁ receptor and the endocannabinoid anandamide: possible antidepressant targets. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1347-1366.	1.5	70
96	Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex. <i>Journal of Neuroscience</i> , 2007, 27, 11700-11711.	1.7	277
97	Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. <i>European Neuropsychopharmacology</i> , 2007, 17, 328-338.	0.3	47
98	N-(Substituted-anilinoethyl)amides: Design, Synthesis, and Pharmacological Characterization of a New Class of Melatonin Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 6618-6626.	2.9	78
99	Efficacy of Topiramate, Valproate, and Their Combination on Aggression/Agitation Behavior in Patients With Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 467-473.	0.7	65
100	Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. <i>Nature Neuroscience</i> , 2006, 9, 1134-1141.	7.1	338
101	Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex. <i>Psychopharmacology</i> , 2006, 185, 255-262.	1.5	71
102	Unusually mild tuberous sclerosis phenotype is associated with TSC2R905Q mutation. <i>Annals of Neurology</i> , 2006, 60, 528-539.	2.8	82
103	Serotonin Firing Activity as a Marker for Mood Disorders: Lessons from Knockout Mice. <i>International Review of Neurobiology</i> , 2005, 65, 249-272.	0.9	2
104	Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18620-18625.	3.3	615
105	Effect of neurokinin-1 receptor antagonists on serotonergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs. <i>Peptides</i> , 2005, 26, 1383-1393.	1.2	65
106	Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. <i>Journal of Psychiatry and Neuroscience</i> , 2004, 29, 208-18.	1.4	44
107	Neurochemical and Psychotropic Effects of Bupropion in Healthy Male Subjects. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 233-239.	0.7	42
108	Title is missing!. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 233-239.	0.7	15

#	ARTICLE	IF	CITATIONS
109	What is a recommended treatment for aggression in a patient with schizophrenia?. Journal of Psychiatry and Neuroscience, 2003, 28, 320.	1.4	6
110	Clonidine fails to modify dopaminergic neuronal activity during morphine withdrawal. Psychopharmacology, 2001, 158, 1-6.	1.5	13
111	Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1912-1917.	3.3	275
112	Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1912-7.	3.3	143
113	Clozapine blocks dopamine, 5-HT ₂ and 5-HT ₃ responses in the medial prefrontal cortex: an in vivo microiontophoretic study. European Neuropsychopharmacology, 1999, 10, 43-49.	0.3	24
114	Alterations of the thalamo-cortical system in rats prenatally exposed to ethanol are prevented by concurrent administration of acetyl-L-carnitine. Brain Research, 1995, 698, 241-247.	1.1	14
115	Growth hormone response to growth hormone-releasing hormone in early abstinent alcoholic patients. Psychoneuroendocrinology, 1993, 18, 475-483.	1.3	7